Search Results - "Mangel, A W"

Gastrointestinal side effects in chronic opioid users: results from a population‐based survey by COOK, S. F., LANZA, L., ZHOU, X., SWEENEY, C. T., GOSS, D., HOLLIS, K., MANGEL, A. W., FEHNEL, S. E.

“…Summary Background  Gastrointestinal side effects are commonly associated with opioid treatment for pain. Aim  To understand gastrointestinal side effects…”
Get full text

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study by Goldberg, M., Li, Y.‐P., Johanson, J. F., Mangel, A. W., Kitt, M., Beattie, D. T., Kersey, K., Daniels, O.

“…Aliment Pharmacol Ther 2010; 32: 1102–1112 Summary Background  Velusetrag is an orally active 5‐HT4 receptor agonist of potential benefit in treating chronic…”
Get full text

Clinical trial: dextofisopam in the treatment of patients with diarrhoea‐predominant or alternating irritable bowel syndrome by LEVENTER, S. M., RAUDIBAUGH, K., FRISSORA, C. L., KASSEM, N., KEOGH, J. C., PHILLIPS, J., MANGEL, A. W.

“…Summary Background  Dextofisopam modulates stimulated activity in animal models of stress, altered bowel motility, and visceral hypersensitivity. Aim  To…”
Get full text

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist by CAMILLERI, M, MAYER, E. A, DROSSMAN, D. A, HEATH, A, DUKES, G. E, MCSORLEY, D, KONG, S, MANGEL, A. W, NORTHCUTT, A. R

“…Background : No currently available treatment provides consistent relief of irritable bowel syndrome. Colonic sensory and motor function are modulated partly…”
Get full text

Determinants of healthcare‐seeking behaviour among subjects with irritable bowel syndrome by WILLIAMS, R. E., BLACK, C. L., KIM, H.‐Y., ANDREWS, E. B., MANGEL, A. W., BUDA, J. J., COOK, S. F.

“…Summary Background Doctor visits for irritable bowel syndrome are associated with high medical costs. Predictors of medical consultation for irritable bowel…”
Get full text

Personal view: adequate relief as a primary endpoint in irritable bowel syndrome by MANGEL, A. W.

“…Summary The success of a clinical trial is judged by achieving statistical and clinical significance on the primary endpoint. This is particularly relevant in…”
Get full text

A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia by Talley, N. J., Van Zanten, S. V., Saez, L. R., Dukes, G., Perschy, T., Heath, M., Kleoudis, C., Mangel, A. W.

“…Background: Functional dyspepsia is characterized by upper abdominal pain or discomfort. Aim: To assess the benefit of the 5‐HT3‐receptor antagonist alosetron…”
Get full text

Study design issues in irritable bowel syndrome by Mangel, A. W.

Get full text

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome by Mangel, A W, Hahn, B A, Heath, A T, Northcutt, A R, Kong, S, Dukes, G E, McSorley, D

“…Irritable bowel syndrome is characterized by recurrent abdominal pain and altered bowel function. In designing studies to evaluate new treatments for this…”
Get more information

Swelling-activated amino acid efflux in the human neuroblastoma cell line CHP-100 by Basavappa, S, Huang, C C, Mangel, A W, Lebedev, D V, Knauf, P A, Ellory, J C

“…1. The effects of hypoosmotic stress on cell volume and amino acid efflux were evaluated in the human neuroblastoma cell line CHP-100 with the Coulter Counter…”
Get more information

Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist by MIURA, M, LAWSON, D. C, CLARY, E. M, MANGEL, A. W, PAPPAS, T. N

“…Irritable bowel syndrome (IBS) represents one of the most common gastrointestinal-related diagnoses. Although the precise etiologic basis of IBS is not known,…”
Get full text

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome by HARDING, J. P., HAMM, L. R., EHSANULLAH, R. S. B., HEATH, A. T., SORRELLS, S. C., HAW, J., DUKES, G. E., WOLFE, S. G., MANGEL, A. W., NORTHCUTT, A. R.

“…Background: The reliability of symptom data collected during efficacy studies in irritable bowel syndrome (IBS) is paramount to the proper assessment of…”
Get full text

Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists by Mangel, A. W., Fehnel, S. E.

“…Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and altered bowel function. Few agents are available for…”
Get full text

Cl- and K+ transport in human biliary cell lines by Basavappa, S, Middleton, J, Mangel, A W, McGill, J M, Cohn, J A, Fitz, J G

“…The cellular mechanisms which contribute to billing secretion and absorption are not fully defined. The purpose of these studies was to evaluate the membrane…”
Get more information

Regulation of cholecystokinin secretion by bombesin in STC-1 cells by Snow, N D, Prpic, V, Mangel, A W, Sharara, A I, McVey, D C, Hurst, L J, Vigna, S R, Liddle, R A

“…Bombesin stimulates cholecystokinin (CCK) secretion, presumably by a direct effect on the intestinal CCK cell. The present objectives were to characterize…”
Get full text

Regulation of high-conductance anion channels by G proteins and 5-HT1A receptors in CHO cells by Mangel, A W, Raymond, J R, Fitz, J G

“…This study addresses the mechanisms responsible for regulation of high-conductance anion channels by GTP binding proteins in Chinese hamster ovary (CHO) cells…”
Get full text

Effects of peptides on gastric emptying [Cholecystokinin] by Mangel, A.W, Koegel, A

“…The effects of peptides on gastric emptying of a liquid meal were studied in rats. Gastric emptying was found to be delayed following intraperitoneal injection…”
Get full text

Phenylalanine-stimulated secretion of cholecystokinin is calcium dependent by Mangel, A W, Prpic, V, Wong, H, Basavappa, S, Hurst, L J, Scott, L, Garman, R L, Hayes, J S, Sharara, A I, Snow, N D

“…The secretion of cholecystokinin was examined in STC-1 cells, an intestinal cholecystokinin (CCK)-secreting cell line. Exposure to the amino acid…”
Get full text

Electrophysiology of intestinal cholecystokinin secretion by Mangel, Allen W.

“…The control of gastrointestinal CCK secretion may occur at several points. A decrease in potassium conductance may depolarize the plasma membrane, activating…”
Get full text

Depolarization-stimulated cholecystokinin secretion is mediated by L-type calcium channels in STC-1 cells by Mangel, A.W. (Duke University Medical Center, Durham, NC.), Scott, L, Liddle, R.A

“…To examine the role of calcium channels in depolarization-activated cholecystokinin (CCK) release, studies were performed in an intestinal CCK-secreting cell…”
Get full text